Gilead Expands Access to Experimental Coronavirus Drug (1)

Gilead Sciences Inc. will expand access to its experimental anti-coronavirus drug remdesivir to accelerate its emergency use for multiple severely ill patients.

The drugmaker said it’s switching to “expanded access” from a “compassionate use” program under which remdesivir was given to more than 1,000 Covid-19 patients.

“With expanded access, hospitals or physicians can apply for emergency use of remdesivir for multiple severely ill patients at a time,” Daniel O’Day, Gilead’s chairman and chief executive officer, said in an open letter sent by email Saturday. “While it will take some time to build a network of active sites, this approach ...